Download MendeleyN-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.
Nirschl, A.A., Zou, Y., Krystek, S.R., Sutton, J.C., Simpkins, L.M., Lupisella, J.A., Kuhns, J.E., Seethala, R., Golla, R., Sleph, P.G., Beehler, B.C., Grover, G.J., Egan, D., Fura, A., Vyas, V.P., Li, Y.X., Sack, J.S., Kish, K.F., An, Y., Bryson, J.A., Gougoutas, J.Z., DiMarco, J., Zahler, R., Ostrowski, J., Hamann, L.G.(2009) J Med Chem 52: 2794-2798
- PubMed: 19351168
- DOI: https://doi.org/10.1021/jm801583j
- Primary Citation of Related Structures:
3G0W - PubMed Abstract:
A novel selective androgen receptor modulator (SARM) scaffold was discovered as a byproduct obtained during synthesis of our earlier series of imidazolidin-2-ones. The resulting oxazolidin-2-imines are among the most potent SARMs known, with many analogues exhibiting sub-nM in vitro potency in binding and functional assays. Despite the potential for hydrolytic instability at gut pH, compounds of the present class showed good oral bioavailability and were highly active in a standard rodent pharmacological model.
Organizational Affiliation:
Discovery Chemistry, Analytical Research & Development, Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, USA.
